Tunnel widening after anatomic double-bundle and mid-position single-bundle anterior cruciate ligament reconstruction.

PURPOSE: The purpose of this study was to compare the amount of postoperative bone tunnel enlargement after anatomic double-bundle (DB) and single-bundle (SB) anterior cruciate ligament (ACL) reconstruction 6 to 8 months after surgery. METHODS: Twenty-one consecutive patients undergoing anatomic 4-tunnel DB ACL reconstruction and 24 patients undergoing anatomic 2-tunnel SB ACL reconstruction were included in this study. In both groups a hybrid fixation technique with interference screw and extracortical fixation at the tibia and an extracortical fixation technique at the femur were used. Magnetic resonance imaging was performed on the second postoperative day and at a mean of 8 months' follow-up (range, 6.8 to 8.3 months) to assess intraoperative and postoperative bone tunnel enlargement. Tunnel widening was determined in different planes by digitally measuring the diameters of the bone tunnels. Tunnel position was measured and classified according to Harner et al. (femoral) and Stäubli et al. and Petersen et al. (tibial). RESULTS: Magnetic resonance imaging showed that all bone tunnels were anatomically placed within the area of the original ACL insertion zone. Compared with the intraoperative drill diameter, we observed only a slight increase in tunnel diameter in both groups on the second postoperative day. At 8 months postoperatively, significant bone tunnel widening occurred in all bone tunnels (P < .001). However, no significant differences were found between tunnel enlargement in the DB group and tunnel enlargement in the SB group (P > .05), either on the tibial side or on the femoral side. In 2 cases tibial tunnel communication was noted at follow-up. CONCLUSIONS: With the use of anatomic SB and DB ACL reconstruction techniques, the results of bone tunnel enlargement were comparable; no significant difference was observed between the tibial and femoral tunnels. LEVEL OF EVIDENCE: Level III, prospective comparative study.

Planning transarterial radioembolization of colorectal liver metastases with Yttrium 90 microspheres: evaluation of a sequential diagnostic approach using radiologic and nuclear medicine imaging techniques.

The purpose of the study was to establish a diagnostic approach to the preparation of patients with colorectal liver metastases considered for transarterial radioembolization (RE). Twenty-two patients sequentially underwent computed tomography (CT; thorax/abdomen), magnetic resonance imaging (MRI; liver; hepatocyte-specific contrast), positron emission tomography (PET/PET-CT; F18-fluoro-desoxy-glucose), and angiography with perfusion scintigraphy [planar imaging; tomography with integrated CT (SPECT-CT)]. The algorithm was continued when no contraindication or alternative treatment option was found. The impact of each test on the therapy decision and RE management was recorded. Patient evaluation using CT revealed contraindications for RE in 4/22 patients (18%). Of the remaining 18 patients, 2 were excluded and 3 were assigned to locally ablative treatment based on MRI and PET results (28%). The remaining 13 patients entered the planning algorithm: SPECT-CT revealed gastrointestinal tracer accumulations in 4 (31%) patients [SPECT, 2 (15%)], making a modified application necessary. In five patients (38%), planar scintigraphy revealed relevant hepatopulmonary shunting. Therapy was finally administered to all 13 patients without therapy-related pulmonary or gastrointestinal morbidity. Each part of the diagnostic algorithm showed a relevant impact on patient management. The sequential approach appears to be suitable and keeps the number of unnecessary treatments and therapy risks to a minimum.

An orthotopic model of pancreatic somatostatin receptor (SSTR)-positive tumors allows bimodal imaging studies using 3T MRI and animal PET-based molecular imaging of SSTR expression.

Somatostatin receptor (SSTR) scintigraphy is currently used as one standard imaging modality in neuroendocrine tumors (NETs). However, future optimization of NET imaging may be achieved with positron emission tomography based methods utilizing more sensitive and specific tracers in combination with computed tomography or magnetic resonance imaging. Here we established an orthotopic mouse model that reflects relevant aspects of human pancreatic NETs such as SSTR expression, dense vascularization and metastatic disease. This model was then utilized to test the feasibility of combined magnetic resonance imaging and animal positron emission tomography. Orthotopic implantation of amphicrine, SSTR-positive pancreatic AR42J cells resulted in rapidly growing tumors, with concomitant metastatic spread into abdominal lymph nodes and peritoneal cavity. Primary tumors as well as their metastases expressed the neuroendocrine markers chromogranin A and synaptophysin. For imaging experiments, the SSTR ligands (68)Ga-DOTATOC or (68)Ga-DOTANOC were injected intravenously, and animals were subsequently examined in an animal positron emission tomography scanner and a clinical 3T (tesla) magnetic resonance imager. All animals showed radionuclide accumulation in the primary tumor. Definite anatomical correlation was achieved using digital image fusion of the positron emission tomography and magnetic resonance imaging data. (68)Ga-DOTANOC strongly accumulated in the tumor tissue (mean 6.6-fold vs. control tissues) when compared to (68)Ga-DOTATOC, which showed a higher renal clearance. In good agreement with the biodistribution data, the kidney-to-tumor ratio was higher for (68)Ga-DOTATOC (2.43-fold vs. 1.75-fold). Consequently, (68)Ga-DOTANOC achieved better signal enhancement in the primary tumor and allowed for detection of metastatic lesions. In summary, we established a novel orthotopic pancreatic SSTR-positive tumor model and used this model to provide proof of principle for the diagnostic combination of SSTR-based molecular imaging and magnetic resonance imaging. Specifically, the animal model allowed the comparative evaluation of (68)Ga-DOTANOC and (68)Ga-DOTATOC, with (68)Ga-DOTANOC providing better tumor-specific accumulation and renal activity. We conclude that this animal model will be of innovative value for further investigation in the imaging of NETs.